MedPath

Ethambutol

Generic Name
Ethambutol
Brand Names
Etibi, Myambutol
Drug Type
Small Molecule
Chemical Formula
C10H24N2O2
CAS Number
74-55-5
Unique Ingredient Identifier
8G167061QZ
Background

Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.

Ethambutol was granted FDA approval on 6 November 1967.

Indication

Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.

Associated Conditions
Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
Clinical Trials
Related News

Essentiality of INH in TB Therapy

First Posted Date
2012-05-02
Last Posted Date
2018-04-06
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
69
Registration Number
NCT01589497
Locations
🇿🇦

TASK Applied Science CRS (31718), Bellville, South Africa

🇿🇦

University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town, Western Cape, South Africa

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

Phase 4
Completed
Conditions
Obesity
Tuberculosis
Interventions
First Posted Date
2010-01-14
Last Posted Date
2013-01-24
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
18
Registration Number
NCT01048697
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

First Posted Date
2008-08-05
Last Posted Date
2017-04-20
Lead Sponsor
Johns Hopkins University
Target Recruit Count
121
Registration Number
NCT00728507
Locations
🇧🇷

Posto de Saude Albert Sabin, Rio de Janeiro, RJ, Brazil

🇧🇷

Hospital Universitario Clementio Fraga Filho, Rio de Janeiro, Brazil

🇧🇷

Centro de Referência Professor Hélio Fraga - ENSP - FIOCRUZ, Curicica, Rio de Janeiro, Brazil

Tuberculosis Treatment Shortening Trial

Phase 3
Completed
Conditions
Tuberculosis
Interventions
First Posted Date
2005-08-15
Last Posted Date
2018-11-08
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
394
Registration Number
NCT00130247
Locations
🇧🇷

Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil

🇺🇬

Mulago Hospital Complex, Kampala, Uganda

🇵🇭

Makati Medical Center, Makati, National Capital Region, Philippines

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
Conditions
HIV Infections
Interventions
Drug: darunavir/ritonavir dosage #1
Drug: TAF w/cobicistat
Drug: elvitegravir/cobicistat
Drug: darunavir/cobicistat
Drug: atazanavir/cobicistat
Drug: lopinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir/tenofovir dosage #1
Drug: lopinavir/ritonavir dosage #2
Drug: indinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir dosage #1
Drug: tipranavir/ritonavir
Drug: darunavir/ritonavir dosage #4
Drug: indinavir/ritonavir dosage #2
Drug: darunavir/ritonavir dosage #2
Drug: lopinavir/ritonavir dosage #3
Drug: lopinavir/ritonavir dosage #4
Drug: tenofovir/atazanavir/ritonavir dosage #2
Drug: atazanavir/ritonavir dosage #2
Drug: darunavir/ritonavir dosage #3
Drug: levoflaxacin
Drug: ethionamide/prothionamide
Drug: terizidone/cycloserine
Drug: para-aminosalicylic acid (PAS)
First Posted Date
2002-08-01
Last Posted Date
2022-07-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1578
Registration Number
NCT00042289
Locations
🇺🇸

Usc La Nichd Crs, Los Angeles, California, United States

🇿🇦

Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa

🇺🇸

Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States

and more 59 locations

TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance

Not Applicable
Completed
Conditions
Tuberculosis
Interventions
Drug: REZ
First Posted Date
2001-09-10
Last Posted Date
2011-08-03
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
98
Registration Number
NCT00023374
Locations
🇺🇸

New York University School of Medicine, New York, New York, United States

🇨🇦

University of British Columbia, Vancouver, British Columbia, Canada

🇺🇸

Washington, D.C. VAMC, Washington, District of Columbia, United States

and more 20 locations

Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS

Phase 3
Completed
Conditions
Mycobacterium Avium-intracellulare Infection
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
400
Registration Number
NCT00001047
Locations
🇺🇸

Henry Ford Hosp, Detroit, Michigan, United States

🇺🇸

Southern New Jersey AIDS Cln Trials / Dept of Med, Camden, New Jersey, United States

🇺🇸

Richmond AIDS Consortium, Richmond, Virginia, United States

and more 13 locations

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Not Applicable
Completed
Conditions
HIV Infections
Tuberculosis
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
525
Registration Number
NCT00000796
Locations
🇺🇸

Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States

🇺🇸

Cook County Hosp, Chicago, Illinois, United States

🇺🇸

Bronx Lebanon Hosp Ctr, Bronx, New York, United States

and more 18 locations

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

Phase 2
Completed
Conditions
Mycobacterium Avium-intracellulare Infection
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
90
Registration Number
NCT00000641
Locations
🇺🇸

St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States

🇺🇸

Washington U CRS, Saint Louis, Missouri, United States

🇺🇸

NY Univ. HIV/AIDS CRS, New York, New York, United States

and more 13 locations

Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

Phase 2
Completed
Conditions
Mycobacterium Avium-intracellulare Infection
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2012-10-31
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT00001039
Locations
🇺🇸

UMDNJ - New Jersey Med School / Cooper Hosp, Camden, New Jersey, United States

🇺🇸

Univ of Maryland at Baltimore, Baltimore, Maryland, United States

🇺🇸

Richmond AIDS Consortium, Richmond, Virginia, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy